Efficacy and safety in genetic and clinical subgroups: Phase III RESONATETM trial of ibrutinib vs ofatumumab in CLL/SLL

Authors :: Ulrich Jaeger
Danelle F. James
Peter Hillmen
Steven Coutre
Stephen P. Mulligan
Nishitha Reddy
Susan O'Brien
John C. Byrd
Jennifer R. Brown
Jacqueline C. Barrientos
Source :: Annals of Oncology. 26:vii96
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
medicine.medical_specialty
chemistry.chemical_compound
chemistry
business.industry
Internal medicine
Ibrutinib
medicine
Hematology
Ofatumumab
business

Tools